Metacrine, Inc. (MTCR)
| Market Cap | 79.58M |
| Revenue (ttm) | 2.18M |
| Net Income (ttm) | -50.22M |
| Shares Out | 26.53M |
| EPS (ttm) | -2.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 319,385 |
| Open | 3.15 |
| Previous Close | 3.10 |
| Day's Range | 3.00 - 3.16 |
| 52-Week Range | 2.59 - 11.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 17.00 (+466.7%) |
| Est. Earnings Date | Nov 11, 2021 |
About MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 17.00, which is an increase of 466.67% from the latest price.
News
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organis...
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present at 2021 Jefferies Healthcare Conference
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virt...
Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD Preclinical data demonstrate synergistic e...
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine to Present at 2021 RBC Global Healthcare Conference
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Confe...
Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily ...
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...
Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...
3 Net-Net Working Capital Stocks
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology
Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that t...
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...
Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH
Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combi...
Metacrine Reports Positive Results from Phase 1 Trial of MET642
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
Metacrine to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...